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Abstract
Systemic sclerosis (SSc) is a rare disorder of the connective tissue characterized by
fibrosis of the skin, skeletal muscles and visceral organs. Additional manifestations
include activation of the immune system and vascular injury. SSc causes disability
and death as the result of end-stage organ failure. Two clinical subsets of the SSc
are accepted: limited cutaneous SSc (lc-SSc) and diffuse cutaneous SSc (dc-SSc). At
present, the aetiology and pathogenesis of SSc remain obscure, and consequently,
disease outcome is unpredictable. Numerous studies suggest that reactive oxidizing
species (ROS) play an important role in the pathogenesis of scleroderma. Over the
years, several reports have supported this hypothesis for both lc-SSc and dc-SSc,
although the specific role of oxidative stress in the pathogenesis of vascular injury
and fibrosis remains to be clarified. The aim of the present review was to report
and comment the recent findings regarding the involvement and role of oxidative
stress in SSc pathogenesis. Biomarkers proving the link between ROS and the main
pathological features of SSc have been summarized.
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1 | INTRODUCTION
Scleroderma (systemic sclerosis, SSc) is an autoimmune disease char-
acterized by vascular abnormalities that include Raynaud’s phe-
nomenon (RP), pulmonary arterial hypertension, fibrosis of skin and
visceral organs. Raynaud’s phenomenon, skin discoloration due to
the abnormal spasm of the blood vessels causing a diminished blood
supply to the local tissues,1 is almost always present and may be so
for several years before the onset of fibrosis. Pulmonary hyperten-
sion is frequent, and anti-centromere antibodies occur in 50%-90%
of patients.2
Two clinical subsets of the SSc are accepted: limited cutaneous
SSc (lc-SSc) and diffuse cutaneous SSc (dc-SSc). The main difference
between these two subsets is the speed of disease progression and
the extent and severity of skin and visceral involvement in lc-SSc;
fibrosis is mainly restricted to the hands, arms and face, while dc-
SSc cases report a higher frequency of heart, lung and kidney
involvement.
The disease mostly affects adult females, with a female:male
ratio ranging from 3:1 to 14:1, suggesting that female sex hormones
may play a role in disease pathogenesis.3 In the EUSTAR register,
the female/male ratio was 6. Modulatory effects of oestrogens, in
particular on extracellular matrix synthesis and the expression of
adhesion molecules, have been observed in the fibrotic progressionPietraforte and Straface contributed equally to this paper.
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of the SSc process via oestrogen receptor interactions.4 The role of
hormones in disease manifestation is also evident when considering
SSc-associated pulmonary arterial hypertension.5 Moreover, autoan-
tibodies to oestrogen receptors have been found to correlate with
disease activity in scleroderma patients.6 Although pulmonary arterial
hypertension occurs more frequently in females, males with this
complication show an increased frequency of other serious SSc dis-
ease manifestations, such as scleroderma renal crisis, diffuse cuta-
neous disease, interstitial lung disease and an increased risk of
mortality.5
Genetic and environmental factors have been suggested to be
involved in the aetiology of this disease, but the exact mechanisms
involved in SSc pathogenesis are not well understood.
Several years ago Murrel 7 linked, for the first time, the patho-
genesis of SSc to the occurring of oxidative stress. Several reports 8,9
have supported this hypothesis for both lc-SSc and dc-SSc, although
the specific role of oxidative stress in the pathogenesis of vascular
injury and fibrosis remains to be clarified. Reactive oxygen and nitro-
gen species (here collectively called reactive oxidizing species, ROS)
are considered the background pathology involved in the develop-
ment of this disease, and heavily contribute to the clinical manifesta-
tions associated with SSc. Indeed, ROS, including superoxide anion
(O2
•), hydrogen peroxide (H2O2), hydroxyl radicals (
•OH), nitric oxide
(•NO), peroxynitrite (ONOO) and hypochlorous acid (HOCl), can
stimulate the production of pro-inflammatory and pro-fibrotic cytoki-
nes (such as PDGF and TGF-b), induce proliferation and activation of
fibroblasts, increase the synthesis of type I collagen and promote
vascular dysfunction.8,9 Studies on animal models have further
strengthened the hypothesis of a role of oxidative stress in the onset
and course of this disease. Skin changes typical for lc-SSc and dc-
SSc have been induced in vivo by the intradermal injection of ROS-
generating compounds.10-12 In addition, targeting of ROS-generating
NADPH oxidase in vitro and in vivo suppresses fibroblast activation
and experimental skin fibrosis.13
2 | EVIDENCE OF OXIDATIVE STRESS IN
SSC PATIENTS
Experimental evidences suggested the occurrence of oxidative stress
in vivo in SSc patients. Samples of either fibrotic or apparently nor-
mal skin from patients with dc-SSc showed higher ROS levels, in par-
ticular O2
•, as compared to healthy control skin, suggesting that ROS
could be initial or intermediate in terms of disease time-line progres-
sion.14 High ROS levels, mainly O2
• and •NO, have been measured
ex vivo in cells from SSc patients, for example in fibroblasts,15,16
monocytes,17 T lymphocytes18 and erythrocytes.19 Likewise, the
total oxidant status of serum from SSc patients has been found to
be higher with respect to control samples.20
Quite high oxidative stress biomarkers in circulating blood have
been found in SSc patients. In a recent meta-analysis involving 47
studies published up to the end of 2015, Luo et al21 reported
increased levels of malondialdehyde (MDA), lipid hydroperoxides and
endogenous •NO inhibitor asymmetric dimethylarginine (ADMA) in
plasma of patients with SSc with respect to healthy controls. MDA
is a stable marker specific to omega-3 and omega-6 fatty acids per-
oxidation. In a case–control study, an inverse relationship was found
between high plasmatic MDA levels and disease duration.22 Riccieri
et al23 found that the increased hydroperoxide levels measured in
plasma of SSc patients correlated with the capillaroscopy semiquanti-
tative rating scale score (predictive of novel future severe organ
involvement in SSc), and with the rating system for avascular areas.
These authors also reported that the levels of carbonyl groups,
biomarkers of protein oxidation, inversely correlated with modified
Rodnan’s skin score, a standard outcome measure for skin disease in
SSc, and were lower in patients with pulmonary fibrosis.
Increased levels of lipid hydroperoxides in cell membranes alter
membrane fluidity and induce loss of membrane protein functions,
and efflux of cytosolic components.24 The plasmatic concentration
of ADMA, an endogenous inhibitor of •NO synthesis, was signifi-
cantly increased in dc-SSc patients but not in lc-SSc patients or in
RP. ADMA is a novel biomarker of endothelial cell dysfunction and
is recognized as an important parameter in determining cardiovascu-
lar mortality and morbidity.25
Another stable marker of oxidative stress is 8-isoprostane, an
eicosanoid prostaglandin-like compound produced by the non-enzy-
matic random oxidation of tissue phospholipids by ROS. 8-Isopros-
tane has a potent vasoconstrictor and platelet pro-aggregating
function and stimulates endothelial cells to bind monocytes, which
may promote vascular obliteration, inflammation and spasm.26 Ele-
vated serum 8-isoprostane levels in dc-SSc and lc-SSC were found
by Ogawa et al27 These Authors demonstrated that the increased 8-
isoprostane levels correlated with the severity of pulmonary fibrosis,
the extent of renal vascular damage and immunological abnormalities
in SSc, suggesting that enhanced oxidative stress is related to the
development of SSc. It has also been reported that serum levels of
8-isoprostane in SSc patients positively correlate with serum heat
shock protein 70 (Hsp70) levels.28 Increased levels of Hsp70 in SSc
patients have been associated with pulmonary fibrosis, skin sclerosis,
renal vascular damage, oxidative stress and inflammation.28
Oxidative post-transcriptional protein modifications, for example,
nitrated proteins, known to be a marker of •NO-derived oxidants,29
and advanced oxidation protein products (AOPP) have been mea-
sured in SSc plasma and skin.30 Interestingly, AOPP in turn seems to
be able to stimulate ROS formation in cell targets. Indeed, serum
containing high AOPP levels isolated from SSc patients has been
found to stimulate endothelial cells and fibroblasts from healthy
donors to generate ROS involved in vascular or fibrotic complica-
tions.30 Interestingly, AOPP generated by different oxidation pat-
terns can induce the selective triggering of cells to produce H2O2 or
•NO, suggesting that these oxidation products may be involved in
the generation of different types of ROS in SSc patients.30 More-
over, urinary levels of both 8-hydroxy-20deoxyguanosine (the main
validated biomarker of endogenous oxidative damage to DNA) and
F2-isoprostane (a product of ROS-mediated arachidonic acid peroxi-
dation) were found to be higher in SSc patients than in controls.31
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The multivariate analysis indicated a relevant association with a
fibrotic phenotype. In fact, 8-hydroxy-20deoxyguanosine levels were
significantly associated with the presence of pulmonary fibrosis,
decreased forced vital capacity and decreased alveolar volume sug-
gesting a potential predictive value of this biomarker.31 Biomarkers
of oxidative stress detected in SSc are listed in Table 1.
3 | PLASMA ANTIOXIDANT CAPACITY IN
SSC
The total antioxidant capacity (TAC), which accounts for the ability
of tissues to counteract oxidative stress, has been reported to be
decreased in plasma of SSc patients.14,15,23,32 The plasma compo-
nents responsible for the antioxidant status are albumin, uric acid,
ascorbic acid, a-tocopherol, b-carotene, bilirubin, glutathione, cys-
teine, dihydrolipoate and ubiquinol. TAC is modulated by the free
radical load, metal concentration and dietary intake of antioxidants
and results from the balance between oxidant species and plasma
antioxidants. The low level of TAC could be the consequence of an
increased ROS production determined by chronic inflammation or by
other pathological conditions such as ischaemia,32 or it could be due
to multiple gastrointestinal manifestations (dysmotility, decreased
pancreatic function, bacterial overgrowth and malabsorption of fat)
that lead to the reduction in nutrient uptake and the increase in
nutrient losses. In this regard, Herrick et al measured decreased
levels of selenium and ascorbic acid independent on dietary regimen,
with lc-SSc patients having even lower levels than dc-SSc patients.33
Interestingly, a possible role of autoantibodies in the reduction
of tissue antioxidant capacity has been hypothesized after the find-
ing of antibodies directed towards ROS detoxifying enzymes, for
example, superoxide dismutase,34 peroxiredoxin35 and methionine
sulphoxide reductase36 in the plasma of SSc patients. Moreover, in
an animal model of bleomycin-induced SSc, subcutaneously injected,
bone marrow-derived, mesenchymal stem cells expressing thiore-
doxin 1 attenuated skin fibrosis and oxidative stress.37
4 | ROS SOURCES IN SSC
Ischaemia reperfusion events, clinically manifested in SSc patients as
RP, have been considered the most likely contributors to the abnor-
mal oxidative stress observed in this disorder.8 ROS production in
SSc tissues could also be triggered by the interaction of cytokines or
growth factors with their specific receptors, such as interleukin-6 (IL-
6), IL-3, tumour necrosis factor a, angiotensin II, platelet-derived
growth factor (PDGF), transforming growth factor b1 (TGF-b1),
nerve growth factor, fibroblast growth factor, and granulocyte–
macrophage colony-stimulating factor.3,8 ROS may be generated
inside the vascular lumen by peripheral blood cells, or within the
vessel wall by monocytes, endothelial cells, erythrocytes and adven-
titial fibroblasts in response to one or more noxious agents (Fig-
ure 1).38 Cells involved in ROS production are reported below.
4.1 | Monocytes
Sambo et al demonstrated that monocytes from SSc patients sponta-
neously release higher levels of O2
• than monocytes from patients
with primary RP or from healthy donors. The generation of O2
• is
sustained through the activation of NADPH oxidase that can be trig-
gered by cytokines such as IL-1, IL-6, IL-8 and TNF-a, whose levels
have been found to increase in SSc patients.17
4.2 | Endothelial cells
Vascular injury and organ devascularization are among the major fea-
tures of SSc. However, the factors that induce endothelial dysfunc-
tion in SSc are still unclear. There are several serological biomarkers
that reflect the vasculopathy of the disease: ROS, endothelin 1 (ET-
1), cell adhesion molecules (eg, E-selectin) and anti-endothelial anti-
bodies. •NO, the potent vasodilator synthesized from L-arginine by
•NO synthase (NOS), is considered to have a biphasic effect in physi-
ological and pathological conditions, being both beneficial and detri-
mental depending on the concentration and local environment.
TABLE 1 Biomarkers of oxidative stress in scleroderma (SSc)
Biomarkers Features Specificity in SSc
Malondialdehyde (MDA) Marker specific of omega-3 and omega-6 fatty acids
peroxidation
High plasmatic MDA levels inversely correlate with
disease duration
Asymmetric dimethylarginine
(ADMA)
Endogenous inhibitor of •NO synthesis, marker of
endothelial cell dysfunction
Significantly increases in dc-SSc patients but not in lc-SSc
patients or in RP
8-isoprostane Produced by the non-enzymatic random oxidation of
tissue phospholipids by oxygen-derived radicals
Correlates with the severity of pulmonary fibrosis
Advanced oxidation protein
products (AOPP)
Generated by different oxidation patterns, stimulate
ROS production
Favour vascular or fibrotic complications
8-hydroxy2deoxyguanosine Marker of endogenous oxidative damage to DNA Associated with the presence of pulmonary fibrosis,
decreased forced vital capacity and decreased alveolar volume
F2-isoprostane Product of free radical-mediated arachidonic acid
peroxidation
Associated with a fibrotic phenotype
Nitrated proteins Product of •NO-mediated protein oxidation Associated with the severity and duration of the disease
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Kundu et al39 measured the bioactive forms of •NO (nitrothiols) in
SSc and found that their levels were very low in plasma of patients
with RP and SSc. With respect to dc-SSc patients, plasma of patients
with primary RP or lc-SSc contained higher concentrations of nitrite
and nitrate, two end-products of •NO metabolism.29 On the other
hand, plasma of patients with dc-SSc contained higher levels of both
ADMA and nitrated proteins, an irreversible post-transcriptional pro-
tein modification induced by the •NO-derived nitrating agents (per-
oxynitrite, nitrogen dioxide radical). Interestingly, the high levels of
nitrated proteins were strongly associated with the severity and
duration of dc-SSc disease.29 Thus, abnormal •NO metabolism in the
plasma of RP, lc-SSc and dc-SSc patients may reflect the underlying
endothelial damage and vasculopathy of SSc diseases. ET-1 is pro-
duced by endothelial cells and is a key mediator of vasculopathy. It
promotes cell growth, arterial wall thickening and endothelial cell
dysfunction, resulting in decreased levels of nitric oxide. Increased
ET-1 production can trigger an inflammatory cascade, raising the
plasma levels of pro-inflammatory cytokines in patients with pul-
monary arterial hypertension.40 ET-1 is over-expressed in both early-
and late-stage SSc, as shown by the elevated levels found in the
blood vessels, lungs, kidneys and skin of SSc patients.41 Adhesion
molecules as E-selectin, sICAM-1 (intercellular adhesion molecule 1)
and sVCAM-1 (vascular cell adhesion molecule 1) are significantly
elevated in SSc patients. E-selectin is produced by the activated
endothelium. Its soluble forms predominate in patients with dc-SSc
vs those with lc-SSc.42 sVCAM-1 is primarily released from endothe-
lial cells, but can be produced by epithelium, dendritic cells and
macrophages. Soluble ICAM-1 can be produced by a variety of cells
including epithelium, leucocytes, hepatocytes and smooth muscle
cells. In SSc, VCAM-1 has been found expressed in endothelial cells
and in skin biopsy specimens,43 while ICAM-1 expressed in fibrob-
lasts,43,44 and infiltrating mononuclear cells.45 Anti-endothelial anti-
bodies (AECAs) are a heterogeneous class of antibodies that have
been identified in the serum of 44%-84% of SSc patients.46 AECAs
are able to activate endothelial cells (EC), induce the expression of
adhesion molecules and trigger EC apoptosis in the presence of NK
cells in vitro.47
4.3 | Red blood cells
Because of their high iron concentration (~20 mmol/L), red blood
cells (RBCs) can be considered as an “iron mine” but, paradoxically,
they also represent one of the major components of blood antioxi-
dant capacity and one of the cells with higher resistance to oxidative
F IGURE 1 Sources of reactive oxidizing species (ROS) in SSc. In SSc, ROS may be generated inside the vascular lumen by activated
monocytes and macrophages, erythrocytes, endothelial cells and fibroblasts. In addition to ROS, activated endothelial cells release adhesion
molecules, which can trigger an inflammatory cascade, elevating the plasma levels of pro-inflammatory cytokines in patients
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stress.48 Crossing inflamed areas, RBCs can help to detoxify ROS,
thus rescuing or partially “protecting” cells (eg, endothelial cells). A
completely different situation may arise when RBCs cross a tissue
where an intense production of ROS occurs. Under these conditions,
RBCs may accumulate oxidative damage, and act as pro-oxidant “bul-
lets” capable of modifying the behaviour and fate of endothelial
cells.49 It has been demonstrated that the systemic oxidative imbal-
ance occurring in SSc patients induces changes in RBCs, including
cytoskeleton oxidative denaturation and derangement, and loss of
lipid asymmetry.6 These changes can result in the alteration of RBC
adhesive properties, aggregability and deformability, and correlate
with disease severity. In agreement, high MDA and •NO levels have
been measured in RBCs of SSc patients.19
4.4 | Fibroblasts
Apart from maintaining the mechanical properties of the skin, dermal
fibroblasts take on an important role in the process of wound heal-
ing by synthesizing collagen and relevant cytokines such as ker-
atinocyte growth factor. Fibroblasts from patients with SSc
constitutively produce a greater amount of ROS such as O2
• and
H2O2, which are responsible for the increased synthesis of type I
collagen. It has been demonstrated that cultured SSc fibroblasts
show an abnormal phenotype that is characterized by the overpro-
duction of different extracellular matrix (ECM) proteins and display
increased constitutive expression of pro-inflammatory factors, for
example, IL-6 and IL-1, and soluble factors that mediate trans-
endothelial migration of mononuclear cells.50 In spite of the high
production of ROS, scleroderma fibroblasts are resistant to Fas-
induced apoptosis. Probably because they have increased levels of
Bcl-2 and decreased levels of Bax. Bcl-2 is an anti-apoptotic, and
Bax is a pro-apoptotic member of the Bcl-2 family.51 Moreover, it
has been demonstrated that both cellular Abelson (c-Abl) and TGF-
b1 serve as apoptosis suppressors in human dermal fibroblasts. c-Abl
is known as a TGF-b1-modulating molecule in fibrosis. TGF-b1 is an
important cytokine that induces fibroblast differentiation into myofi-
broblasts and is considered to be the major factor towards chronic
fibrosis. SSc patients express elevated TGF-b1 levels in the early
lesions, but not in established fibrotic tissue.52 Kim and collaborators
demonstrated that TGF-b1 induced the activation of Akt in normal
and RA synovial fibroblasts, and that TGF-b1 exerted its anti-apop-
totic effect, in part, through the PI3 kinase/Akt pathway.53
5 | ANTIOXIDANT THERAPY FOR SSC
A reduced concentration of classical antioxidants, such as antioxidant
vitamins (ascorbic acid, a-tocopherol, and b-carotene) and minerals
(zinc, selenium), has been found in RP and SSc. This antioxidant
potential deficiency increases the propensity to oxidative stress,
favouring the development of injury mediated by ROS generation.
Currently, molecules as N-acetyl-l-cysteine (NAC), antioxidant vita-
mins and polyphenols may be useful in the supportive therapy of
SSc and RP. NAC acts as a precursor for the substrate (l-cysteine) in
the synthesis of hepatic glutathione (GSH), and replenishes GSH in
deficient cells. It influences protein thiols, supports glutathione syn-
thesis and generates free sulfhydryl groups. In many studies, NAC
has shown a beneficial influence on SSc, diminishing cellular ROS in
fibroblast and replenishing free cellular thiols.54 Vitamin E is a potent
intracellular antioxidant55 and protects the polyunsaturated fatty
acids present in membrane phospholipids and in plasma lipoproteins.
Moreover, its administration considerably increases cell-mediated
and humoural immune functions in human.56 Polyphenols are natural
antioxidants present in many plant foods. Among these, ()epigallo-
catechin-3-gallate (EGCG) present in green tea extracts (Camellia
sinensis) is effective in eliminating oxidative stress in SSc. It is a scav-
enger of free radicals, inhibits the formation of ROS such as O2
•, and
peroxynitrite and reduces oxidative stress.57 However, some clinical
trials have shown that the treatment with antioxidants has had lim-
ited success. Literature data report that: (i) a 3-week vitamin E treat-
ment at doses of 500 or 1000 mg/day neither reduced the basal
rate of lipid peroxidation nor improved microvascular perfusion fol-
lowing cold exposure56; (ii) ascorbic acid did not improve endothelial
vasomotor dysfunction in the brachial circulation of patients with RP
secondary to systemic sclerosis58; and (iii) no clinical benefit was
observed in SSc patients after an active treatment with a combina-
tion of micronutrient antioxidants (selenium, beta-carotene, vitamin
C, vitamin E and methionine) and allopurinol.59
There are several possible explanations for these poor results,
for example, (i) the short duration of therapy. It is possible that in
order to be effective, the antioxidant therapy has to be given early
in the SSc disease process, before the onset of irreversible tissue
damage; (ii) the malabsorption syndrome resulting from increased
collagen deposition in the intestines or bacterial overgrowth in SSc
patients; and (iii) an altered renal clearance of the aqueous phase
antioxidants (such as ascorbic acid) and its increased excretion in SSc
patients.
Although recent findings supporting the efficacy of antioxidant
therapy are very encouraging,54-56,58 further studies are necessary to
define the therapeutic potential of the analysed antioxidants in SSc.
Anyway, notwithstanding substantial advancements, the morbid-
ity and mortality in SSc are still high and can largely be attributed to
a delay in diagnosis. In fact, at the time of diagnosis, SSc is often
well established with significant irreversible tissue and organ
damage. An early and accurate diagnosis of SSc and the use of
autoantibody testing embedded in evidence-based clinical care
pathways will help improve SSc-associated clinical outcomes and
healthcare expenditures.
6 | CONCLUSIONS
This review comments on the recent findings regarding the involve-
ment and the role of oxidative stress in SSc pathogenesis.
Biomarkers proving the link between ROS and the main pathological
features of SSc could be of interest in the development of more
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appropriate diagnostics and therapeutic strategies. In fact, the patho-
genesis of SSc appears as complex and involves a complex frame-
work of “actors” such as endothelial cells, epithelial cells, fibroblasts
and immunological mediators, resulting in dysregulated vascular
remodelling and, ultimately, vasculopathy. In addition, taking into
account the significant gender disparity in the occurrence of the dis-
ease as well as the well-known differences in ROS generation by XX
and XY cells, including vessel cells,60 the relevance of the redox
state as a gender-associated determinant in the disease onset and
progression cannot be ruled out.
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